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ABSTRACT 
Objective: The study aimed to develop and evaluate an orally disintegrating tablet that contains pilocarpine and 2-hydroxy propyl β-cyclodextrin as 
an inclusion complex that is prepared by lyophilization used for treatment for dry mouth. Pilocarpine is utilized to treat dry mouth disorder. The 
inclusion complex lowers the taste of pilocarpine through the oral mucosa by the use of 2-hydroxy propyl β-cyclodextrin. 
Methods: The in vitro release from the insertion complex is also been studied. The parameters like differential scanning calorimetry (DSC), Fourier 
transformer infrared spectroscopy (FTIR), X-ray diffraction (XRD), and morphological study have been evaluated. The design of an experiment is 
carried out based on the concentration of croscarmellose sodium (CCS) and microcrystalline cellulose (MCC). Evaluation of the prepared orally 
disintegrating tablets have been carried out by different test methods like weight variation, thickness, drug content, disintegration, and in vitro 
dissolution study.  
Results: Orally disintegrating tablets are studied by utilizing the immediate pressure technique. Pilocarpine indicates the anhydrous crystalline 
medication, displaying sharp endothermic top at 120.2 °C, bend of 2-HPβCD demonstrates an exceptionally wide endothermal wonder among 55-
100 °C for DSC. In pilocarpine spectra, characteristic band of aromatic C-H stretch at 3277 cm-1, C=C stretching at 1608 cm-1, C-N stretching at 1445 
cm-1 and methoxy (CH3-O-) stretch at 2921 cm-1 was observed. The investigation shows that tablet hardness of 4.3N, breaking downtime of 12 sec 
and mean disintegration time is 1.562 min. 
Conclusion: The different diluents and super disintegrating have been applied for the quick elevation of dry mouth that helps us for patient 
compliance. 
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INTRODUCTION 
Orally disintegrating tablets are normally compelled using a direct 
compaction technique as this is the easiest and most money-making 
production process. Choosing excipients is considered as chief 
limitations establishing the property of an orally disintegrating tablet. 
Disintegrant, binder, glider, lubricant, sweeteners, and masking agent for 
taste were employed for the formulation [1]. Dissolving in diluents 
affects the mechanism of dissolutions and break down of formulation. 
Disintegrant and diluents concentration has a strong impact on the time 
of disintegration and the mechanism of dissolution. Tablet breaking time 
optimization can be reached by determining the optimal disintegrant 
and diluents amounts [2, 3]. The breakdown period is negatively 
proportional to the breakdown rate below critical absorption and more 
than this breakdown period, it resides mostly persistent. Hence, their 
attributes will be affected by modifying the proportion and 
centralizations of diluents and breaks down in orally disintegrating 
tablets articulation [4]. Organic cyclodextrin cyclic oligosaccharide with 
6-(α-cyclodextrin), 7-(βcyclodextrin) either 8-glucopyranose unit 
attached to the macrocycle by α-1 4-glycoside bonds. It has an outer 
layer of hydrophilic and a hydrophobic cavity [5]. 
After complexation, the physicochemical property of the visitor 
atom involved is reform and the insertion complexes were used to 
increase stability, solubility, rate of dissolution, and bioavailability. 
Through encasing the utilitarian gathering liable for the severe taste 
inside the depression, they can likewise diminish the unpleasant 
taste of very harsh items [6].  
Pilocarpine is a characteristic compound got from Pilocarpus 
jaborandi, a South American shrub. This plant alkaloid is a 
cholinergic parasympathomimetic agonist that ties to muscarinic-
M3 receptors and can trigger pharmacological smooth muscle 
compression in people and incitement of different exocrine glands 
[7]. Pilocarpine hydrochloride tablets are shown for analysis of 
radiation-initiated dry mouth. 
Pilocarpine HCl-2-Hydroxy Propyl β-cyclodextrin insertion composite 
depending upon orally disintegrating tablets was suggested in this 
present investigation. The insertion complex limits the harsh taste of 
Pilocarpine HCl in the plan while upgrading the ingestion penetrability 
through the oral mucosa [8]. Oral mucosa is where orally disintegrating 
tablets formulations are utilized. These perplexing acknowledgments 
based on orally disintegrating tablets are perfect for populaces 
confronting trouble gulping regular Pilocarpine HCl unpleasant tasting 
tablets [9]. 
MATERIALS AND METHODS 
Materials 
Pilocarpine Hydrochloride was purchased from Merck Specialist Pvt. 
Ltd., Mumbai, India. The 2-Hydroxy Propyl β-cyclodextrin (2-
HPβCD) is procured from Hi-Media Lab. Pvt. Ltd., India, Mannitol is 
obtained from SRL Pvt. Ltd., Bombay, India. Croscarmellose sodium 
(CCS) and microcrystalline cellulose (MCC) were obtained from 
LOBA Chemical Pvt. Ltd., Mumbai, India. Sodium stearyl fumarate 
was supplied from Merck Specialist Pvt. Ltd., Mumbai, India. Other 
reagents and solvents were utilized for logical evaluation. Deionized 
water was used throughout the investigations. 
Methods 
Phase solubility study 
Based on the procedure reported before by Higuchi and Connors, 
1965, the stage solvency study was carried out. The graph of stage 
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solvency was procured in the water at pH 7. A surplus of Pilocarpine 
(200 mg) was applied in screw-cap glass vials consisting of an 
expanded sum of 2-HPβCD (range 0-0.025 M) to 10 ml of liquid. The 
vials are installed in a thermo-shaker and continuously shaken at 
500 rpm at 37±0.5 °C. After meeting equilibrium, the suspensions 
were stirred for 48 h. The sample solutions were filtered and 
adequately diluted via a 0.20 μm membrane filter after equilibrium 
is achieved. The solubilized pilocarpine was calculated by an HPLC 
method described below in different concentrations of the 2-HPβCD 
solution and triplicate tests were performed [10]. Previous findings 
showed that 2-HPβCD at the concentration used will not inquisitive 
the HPLC resolution. According to the formula, the stability constant 
(Ks) was determined from the stage dissolvability figure, assuming 
1:1 stoichiometry (because the slope is less than 1). 
Preparation of the inclusion complex 
Lyophilized insertion composite is composed of solubilizing the 
precise sums (molar ratio) of pilocarpine with 2-HPβCD at ambient 
temperature (27±1 °C) in deionized water. The resulting solution 
was frozen for 48 h. at -50 °C and 0.03 Mbar (MODULYO, Edwards 
UK). The insertion composite was triturated then passed by 60 mesh 
sieving instrument and reserved until further analysis was done in 
light-preserved desiccators. Also, the physical blend was set up via 
cautious blending of the precise rate (molar proportions) of 
pilocarpine and 2-HPβCD and parallel mixture inside the fired 
mortar (12 min). 
Differential scanning calorimetry (DSC)  
Estimation is done to determine unadulterated pilocarpine, 
unadulterated 2-HPβCD, 1:1 corporal blend and 1:1 consideration 
complex was done utilizing a DSC-60 (SHIMADZU, Kyoto, Japan). The 
DSC investigation considered adjustment with the pace of warmth 
consumed by pilocarpine in elaboration with 2-HPβCD [11]. 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectroscopy of unadulterated pilocarpine, unadulterated 2-
HPβCD, 1:1 physical mixture, and 1:1 consideration complex was 
utilized by an FTIR-8400S spectrometer (SHIMADZU, Kyoto, Japan) 
outfitted with germanium precious stone. Spectroscopy accession is 
executed legitimately with granule tests by utilization with 63 
sweeps at a goal of 2 cm-1[12]. 
Powder X-ray diffraction 
This is done by utilizing pilocarpine, 2-HPβCD, physical mixture, 1:1 
consideration complex were gathered utilizing X-ray diffraction 
furnished with fast indicator and CuKα origin with a charge of 43 kV, 
and a current of 40mA. The unadulterated Pilocarpine, unadulterated 
2-HPβCD, physical mixture, and 1:1 consideration complex were 
inspected utilizing Zeiss EVO LS 15, Smart SEM Germany. The sample 
is attached on a metal stub utilizing a two fold side and afterward by 
shower covering in space with a flimsy sheet at 0.6 kV [13]. 
Tablet compression of inclusion complex 
Design of experiments  
The focal complex structure comprises a partial plan whose focal 
focuses that these are enlarged to a gathering of pivotal points, 
which results in the estimation of curvature. In a face-focused focal 
composite plan, star focuses are at the focal point of factorial 
structure focuses. Two factors, three levels face focused focal 
complex plan is utilized for the streamline of variables. Components 
are assessed with high levels, medium, and low (+1, 0, and-1) [14]. 
  
Table 1: Factorial central composite design (CCD) 
Liberated variables Formulation Design level Coded level 
CCS, X1 (mg) A 0 low -1 
6 Medium 0 
12 high 1 
MCC, X2 (mg) B 0 low -1 
60 Medium 0 
120 high 1 
Note: CCS, X1-Diluent Croscarmellose sodium; MCC, X2-Superdisintegrant Microcrystalline cellulose; CCD–Central Composite Design 
 
Tablet manufacturing 
Pilocarpine-2-HPβCD physical mixture is sieved with #40 work 
strainer previous to blending. Different additives were precisely 
gauged and blended out and out in with Pilocarpine-2-HPβCD 
consideration complex for 15 min. Sodium stearyl fumarate was mixed 
with the mix then greased up for 7 min additional in a blender. Tablets 
are packed with a solitary punching instrument utilizing 0.370 inch. 
 
Table 2: Pilocarpine loaded ODT formulations 
Ingredients Weight (mg) 
Pilocarpine-2-HPβCD complex 12* 
Croscarmellose Sodium 0/5/10 
Microcrystalline Cellulose 0/50/100 
Sodium Stearyl Fumarate 1.8 
Flavoring agent 1.8 
Mannitol q. s 
Note: *Incorporation composite granule comparable with 10 mg 
Pilocarpine; q. s= Quantity sufficient; 2-HPβCD-Hydroxyl propyl β 
cyclodextrin; ODT-Oral disintegrating tablet 
 
Evaluation of prepared ODT’s 
Variation in weight 
Weight variety of all clumps of Oral Disintegrating Tablets (ODTs) is 
surveyed. 20 tablets from all bunch are separately gauged along with 
normal mass are accounted. 
Thickness 
Reweighed ten tablets from all groups are tried. A micrometer was 
utilized to gauge the normal thickness and standard deviation was 
accounted. 
Friability 
Twenty tablets of the formulation are gauged along with estimated 
in friabilator (Electro lab Mumbai India). Turn acceleration is set to 
30 rpm with 5 min, and tablets are re-gauged. Rate friability is 
determined by utilizing the condition. 
Content of drug 
Three tablets are weighed independently for all clusters and 
squashed in an earthenware mortar. Precisely gauged amounts of 
amorphous tablets (595 mg) are separated with pH 6.7 phosphate 
cradles. The investigations are utilized thrice with normal qualities 
and standard deviations are accounted. 
Hardness 
All groups containing 10 tablets with concise mass are inspected for 
the hardness of tablets utilizing a hardness tester. The normal 
hardness and standard deviation for each bunch were accounted [15]. 
Wetting time and water absorption ratio 
A tissue paper of size 14 × 14 cm is collapsed two times and set in 
the watch glass (8 cm breadth) consisting of 5 ml water. Tablet is set 
over the tissue paper and the time need for water to arrive at the top 
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layer is considered to be wetting time. Investigations are done 
thrice. Water retention proportion (R) is resolved to utilize the 
accompanying condition [16] 
In vitro dissolution test 
ODT is assessed for dissolution conduct. Dissolution analysis is 
executed according to USP necessities with prompt discharge dose 
structures utilizing USP II mechanical assembly paddle technique 
[17]. Dissolution was completed in 900 ml phosphate support pH 6.7 
with 70 rpm and 36.5±0.6 °C. Dissolution with pH 6.7 is maintained, 
which reproduces pH states with salivation liquid [18].  
Statistical analysis and optimization 
The measurable mode in association with terms is determined to 
assess the impact of 2 factors (X1 and X2) with reaction factors: 
hardness of tablet (Y1), deterioration time (Y2) also, mean 
disintegration time-MDT (Y3). Polynomial models were produced for 
each reaction factor [19]. The investigation leads to a direct mode 
which is utilized for the decision of relationship among elements 
with reaction factors (Y1) and quadratic models for deciding the 
connection among components and reaction factors (Y2)/(Y3).  
RESULTS AND DISCUSSION 
Phase solubility study 
Stage solvency graph is acquired at 37.5 °C by plotting the obvious 
dissolvability of pilocarpine versus expanding grouping of 2-
hydroxy propyl β-cyclodextrin. It is seen that the solvency of 
pilocarpine from composite expanded straightly with a component 
of 2-HPβCD fixation. The stage solvency profile (straight plot) was 
delegated AL type. These AL-type bends show the development of 
water solvent edifices among pilocarpine and 2-HPβCD with a 1st 
request reliance connection of 2-Hydroxy propyl β-cyclodextrin 
fixation [20]. This straight substrate-ligand connection with slant 
esteem under 1 proposed the development of first request solvent 




Fig. 1: Phase solubility for Pilocarpine 2-HPβCD insertion composite, *mean±SD (n=3) 
 
Content of drug in insertion complex 
Real medication consisting of the corporal blend and lyophilized 
composite are analyzed. Results are accounted. As found in the table, 
both physical mixture with lyophilized composite demonstrated a 
decent understanding of hypothetical and real medication content. The 
standard deviation of the physical mixture was found to be 94.38±0.55 
% and the lyophilized mixture was found to be 95.48±0.97%. 
 
Table 3: Drug content in the inclusion complex (mean±SD) 
Mixtures Theoretical range mean±SD* 
Physical mixture 100.0 94.38±0.55 
Lyophilized mixture 100.0 95.48±0.97 
Note: *mean±SD(n =3) 
 
Characterization of inclusion complex 
Differential scanning calorimetry  
Differential scanning calorimetry bends for Pilocarpine, 2-
hydroxypropyl β-cyclodextrin, physical mixture, and Lyophilized 
Pilocarpine-2-hydroxypropyl β-cyclodextrin in corporation composite 
considered is accounted [21]. Pilocarpine indicated the run-of-the-mill 
conduct of anhydrous crystalline medication, displaying a sharp 
endothermic top at 120.2 °C, relating to liquefying purpose for 
medication. The DSC bend of 2-HPβCD demonstrated an exceptionally 
wide endothermal wonder among 55-100 °C, because of the arrival of 
water atoms. The corporal blend of pilocarpine and 2-hydroxy propyl 
β-cyclodextrin indicates an endothermic top, 125 °C. The physical 
mixture of pilocarpine with 2-HPβCD showed the endothermic peak at 
120 °C but with a decreased enthalpy of reaction. The complete 
disappearance of the pilocarpine endothermic peak was observed for 
lyophilized pilocarpine 2-HPβCD inclusion complex indicating the 
encapsulation of drug molecule inside the cavity or formation of the 
amorphous complex or both. 
Fourier transforms infrared spectroscopy 
Fourier transform infrared spectra explored utilitarian gatherings 
with pilocarpine engaged with the complexation gives strong proof 
of complex development [22]. The FTIR spectra of every one of the 
examples are displayed in the figure. In pilocarpine spectra, the 
characteristic band of aromatic C-H stretch at 3277 cm-1, C=C 
stretching at 1608 cm-1, C-N stretching at 1445 cm-1,and methoxy 
(CH3-O-) stretch at 2921 cm-1 was observed and used to determine 
the interaction between 2HPβCD and pilocarpine in the solid-state. 
FTIR spectra for 2-HPβCD shows O-H stretching at 3290 cm-1. 
Spectra for both the physical mixture and lyophilized complex did 
not show new peaks indicating that no chemical bonds were created 
in the formed complex; however, shifting of the characteristic peak 
at 1445 cm-1 towards a lower wavenumber (1358 cm-1) in 
lyophilized the inclusion complex was seen. This suggests the 
formation of hydrogen bonds between the amino group of 
pilocarpine and the hydroxyl groups of the cyclodextrin cavity. The 
amino group of pilocarpine is responsible for the bitter taste of the 
drug. From these findings, it can be postulated that the complexation 
of the bitter-tasting amino functional group inside the cavity 
drastically reduces the bitterness of pilocarpine. In the physical 
mixture, characteristic peaks of pilocarpine were still detected with 
low intensity. 
X-ray diffraction  
Powder X-ray diffraction design is made with unadulterated 
pilocarpine displayed a few diffraction tops demonstrating the 
crystalline idea of the medication as appeared in fig. 4. 
Conversely, 2-HPβCD was available in a nebulous structure. The 
1:1 physical blend additionally displayed a common diffraction 
design yet force contrasted with the diffraction design for the 
unadulterated medication. The 1:1 physical mixture also 
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exhibited a typical crystalline diffraction pattern but of less 
intensity compared to the diffraction pattern for the pure drug. 
This confirmed the presence of pilocarpine in its crystalline form 
in the 1:1 physical mixture and no inclusion complex was 
formed. It also showed a weak interaction between drug and 
cyclodextrin in the physical mixture, confirming the DSC results. 
Pilocarpine-2-HPβCD inclusion complex displayed diffuse 
diffraction patterns (identical to that of 2-HPβCD without drug 
peaks), suggesting the entirely amorphous nature of pilocarpine 
in 1:1 lyophilized complex [22]. 
 
 
Fig. 2: Differential scanning calorimetry thermograms for Pilocarpine (A), 2-HPβCD (B), 1:1 mixture, (C) and 1:1 lyophilized (D) 
Pilocarpine 2-HPβCD insertion composite *2-HPβCD= Hydroxyl propyl β cyclodextrin 
 
 
Fig. 3: FTIR spectra for pure Pilocarpine (A), pure 2-HPβCD (B), and physical, Mixture (C) and lyophilized (D) Pilocarpine 2-HPβCD 
insertion composite, *2-HPβCD= Hydroxyl propyl β cyclodextrin 
 
 
Fig. 4: XRD of pilocarpine (A), 2-HPβCD (B) physical mixture(C) and Lyophilized Pilocarpine2-HPβCD (D) insertion composite, *2-HPβCD= 
Hydroxyl propyl β cyclodextrin 
Gowda et al. 
Int J App Pharm, Vol 13, Issue 2, 2021, 217-223 
221 
Dissolution study 
Dissolution profile was done for unadulterated Pilocarpine, corporal 
blend, and lyophilized blend and every one of the details dissolved 
around 90% of the Pilocarpine shortly [23]. Dissolution parameters, 
its productivity following 10 min (DE10 min), and level of 
medication dissolved following 4 min (DD4 min) were estimated for 
all plans as showed in table. 
  
Table 4: Dissolution parameters for pilocarpine in pure, physically mixed and lyophilized form 
Parameter Pilocarpine 1:1 corporal blend±SD 1:1 lyophilized blend±SD* 
DD4 min (%) 41.23±2.14 69.03±4.12 89.23±2.56 
DE10 min (%) 54.23 65.54 80.254±7.56 
Note: *mean±SD (n=3), DD= Drug dissolved, DE= Dissolution efficiency 
 
There were critical contrasts in dissolution profiles for unadulterated 
medication, corporal blend, and lyophilized blend. Accounting DE10 min 
esteems, dissolution pace for Pilocarpine was expanded in the request: 
unadulterated medication less than 1:1 corporal blend less than 1:1 
lyophilized blend proposing that dissolution flow is affected by 
lyophilization technique used to set up incorporation complex [24]. 
Following 4 min, the level of unadulterated medication broken down 
was 41.23% in any case, the rate medicates dissolution from the physical 
blend, lyophilized complex was 69.03%, and 89.23% individually. 
Orally disintegrating tablets characterization and evaluation 
Tablet definitions are set up as indicated by the planning 
framework that appeared in fig.; dependent on formulae 
referenced in fig. 5. Pilocarpine orally disintegrating tablets 
property for example, weight, thickness, friability, wetting period 
and water assimilation proportion, and medication content 
consistency were appeared [25]. Tablet plans met those 
prerequisites in terms of weight variance, thickness, friability, 
wetting period, and water assimilation proportion. Medication 
contents consistency ran from 97.3% to 103.7% and was inside 
the worthy limits. As shown in table 5, formulation F2 is having a 
medium concentration of MCC, whereas formulations F6, F7, F12 
without MCC replicates more wetting time as compared to other 
formulations. Similarly, for water absorptions ratios, F1, F3, and 
F8 are having higher MCC concentrations and F6, F7, and F12 are 





Fig. 5 (A-C): Effect of formulation factors on characteristic response variables of Pilocarpine *mean±SD (n=3) 
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Table 5: Pilocarpine analysis for each experimental run 




Drug content uniformity 
Percentage RSD 
F1 200.83±4.41 3.28±0.012 4.40±0.49 105.78±5.60 0.928 101.98 2.58 
F2 201.87±3.35 2.48±0.011 133.15±7.41 58.22±8.5 0.103 100.64 2.60 
F3 200.51±2.24 3.31±0.014 4.19±0.25 131.47±2.94 0.964 100.89 1.15 
F4 199.14±1.59 2.54±0.006 47.46±5.47 56.34±14.05 0.649 98.94 2.49 
F5 200.41±3.24 2.55±0.014 51.49±2.79 42.60±3.31 0.569 102.91 1.90 
F6 200.38±3.36 2.41±0.018 104.45±4.86 17.11±1.96 0.875 103.69 1.28 
F7 201.08±4.70 2.25±0.015 131.26±8.68 19.91±8.06 0.599 98.85 1.19 
F8 195.91±1.54 3.92±0.015 2.40±0.38 156.45±9.30 1.060 97.29 0.94 

















F12 201.82±2.26 2.26±0.018 214.27±7.41 18.39±5.98 0.352 100.92 2.74 
F13 201.41±3.31 2.91±0.014 18.12±3.17 75.25±7.54 0.660 102.45 1.07 
Note: RSD: Relative Standard Deviation, mean±SD (n=3) 
 
In fig. 5(A) and table 6, formulation with low croscarmellose sodium 
concentration and without MCC and formulation without CCS and 
MCC were found to have maximum hardness when compressed into 
tablets. Mannitol was used as a filler and these formulations had 
high concentrations of mannitol due to the absence of CCS and MCC.  
In fig. 5(B) and table 6, Formulations F2, in the absence of CCS 
showed an increase in disintegration time. Formulation F6 and F7, in 
the absence of MCC, showed similar effects. Besides, the formulation 
F12 (in the absence of both MCC and CCS) also increased the 
disintegration time. This reflects that the concentration of 
croscarmellose sodium and microcrystalline cellulose combined or 
alone has a strong influence on the disintegration time. Formulation, 
F1 with a high concentration of MCC and an absence of CCS, showed 
a disintegration time within one minute. This can be attributed to 
the disintegrant properties of MCC at higher concentrations. All 
other formulations in the presence of CCS and MCC showed 
disintegration of tablets within one minute. 
The design of experiments (DoE) is embraced to upgrade basic 
detailing factors dependent on its impact on trademark reactions 
that influence presentation for orally crumbling tablets. Trademark 
reactions incorporate tablet Hardness, breaking downtime, and 
Mean Disintegration Time. The investigation shows that tablet 
hardness of 4.3N, breaking downtime of 12 sec, and mean 
disintegration time is 1.562 min [26]. 
  











F1 0 120 3.98±0.25 10.56±1.58 3.19 
F2 0 60 8.14±0.68 105.41±3.58 5.93 
F3 6 120 3.99±0.31 9.86±5.25 1.54 
F4 6 60 7.55±0.22 34.14±2.18 1.33 
F5 6 60 7.89±0.23 30.16±0.54 1.02 
F6 6 0 6.97±0.69 130.47±3.74 4.88 
F7 12 0 11.09±0.75 131.41±2.74 5.16 
F8 12 120 1.94±0.45 5.42±2.12 1.54 
F9 6 60 2.18±0.89 12.43±3.16 2.14 
F10 12 60 2.26±0.68 10.26±1.54 1.36 
F11 6 60 2.58±0.61 14.12±3.48 1.28 
F12 0 0 10.93±0.76 242.15±1.33 6.10 
F13 6 60 4.32±0.49 18.80±1.83 1.57 
Note: *MCC: Microcrystalline Cellulose *MDT: Mean Disintegrating time *mean±SD (n=3)  
 
Table 7: ANOVA for tablet hardness (Y1), disintegration time (Y2) and mean dissolution time (Y3) 
Source Sum of Squares Degree of 
freedom 
F value p-value Prob>F 
Y1 Y2 Y3 Y1 Y2 Y3 Y1 Y2 Y3 Y1 Y2 Y3 
Model 71.12 61451.15 35.14 2 7 5 7.56 114.25 11.20 0.0106* 0.0001* 0.0041* 
X1-CSS 12.45 4598.58 9.65 1 1 1 2.45 60.54 14.99 0.1222 0.0004* 0.0061* 
X2-MCC 56.45 7594.15 11.25 1 1 1 10.98 102.25 18.14 0.0061* 0.0019* 0.0042* 
X1X2 - 1689.79 0.11 - 1 1 - 21.89 0.19 - 0.0046* 0.6785 
X12 - 2996.14 7.01 - 1 1 - 38.96 11.30 - 0.0013* 0.0149* 
X2 2 - 5792.96 1.45 - 1 1 - 76.49 2.98 - 0.0003* 0.1598* 
X12 X2 - 906.39 - - 1 - - 10.47 - - 0.0166* - 
X1 X2 2 - 746.95 - - 1 - - 09.91 - - 0.0220* - 
Residual 47.25 358.48 4.36 10 5 7 - - - - - - 
Lack of Fit 24.14 106.84 4.35 6 1 3 0.65 1.48 547.12 0.6458 0.2658 0.0001* 
Pure Error 22.45 241.15 0.112 4 4 4 - - - - - - 
Cor total 120.48 60956.56 40.15 12 12 12 - - - - - - 
Note: *Represents significant model terms with P-value<0.05 
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Mathematical modeling of data obtained from experimental 
design 
Thirteen experiments were held to design the concentration of 
croscarmellose sodium (X1) and microcrystalline cellulose (X2) on the 
tablet hardness (Y1), disintegration time (Y2), and mean dissolution time 
(Y3) [17]. Data for the CCD runs are presented in table 6. The measured 
responses are illustrated in fig. 5 (a-c) and show that a selected 
formulation factor has a strong bonding on the selected results. 
ANOVA was done to explain the importance level and magnitude of the 
effects of process variables and interaction between the variables. The 
results confirm the adequacy of the model (P<0.05) as shown in table 
7. The model depicts the important factors (X1 and X2) that affect the 
responses (Y1, Y2, and Y3) of Pilocarpine. The hardness of the tablet, 
concentration of microcrystalline cellulose (MCC) was important; 
however, the concentration of croscarmellose sodium (CCS) was not 
important. In disintegration times and mean dissolution times for 
ODTs, the concentration of both CCS and MCC were important. The 
interaction between the main variables (X1X2) was important for 
disintegration time (Y2); however, the interaction between MCC and 
CCS were not important for tablet hardness (Y1) and MDT (Y3) 
The opposing impacts of X1 and X2 were minor as for tablet hardness 
(Y1) and mean disintegration time (MDT) (Y3) when contrasted with 
deterioration time (Y2). The association impact somewhere in the 
range of X1 and X2 and quadratic impacts were minor regarding 
(MDT) (Y3) when contrasted with breaking downtime (Y2). 
CONCLUSION 
The Oral Disintegrating Tablets plan of Pilocarpine was prepared. 
Lyophilized incorporation composite for Pilocarpine and 2-HPβCD 
improve disintegration amount and demonstrated capacity for 
covering of harsh flavor for medication that is essential of readiness 
for oral breaking down tablet as application. Flavor veiling capacity 
and system for incorporation composite as suggested dependent on 
the portrayal of the lyophilized consideration complex powder 
utilizing as extreme portrayal apparatus. Pilocarpine orally 
disintegrating tablets were effectively arranged utilizing the 
Pilocarpine-2-Hydroxy propyl β-cyclodextrin lyophilized composite 
powder. Few parts which influence the property of Pilocarpine Oral 
Disintegrating Tablets are arranged by consideration composite. 
Arrangement for diluents and super disintegrants enhanced the 
utilizing reaction surface approach with the focal composite 
structure to acquire fast disintegration and crumbling with adequate 
tablet parameters which improved medication ingestion for Oral 
Disintegrating Tablets in oral mucosa delivering quick alleviation 
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